Abstract
Objective To develop a harmonized multicenter clinical and electroencephalography (EEG) database for acute hypoxic-ischemic brain injury research involving patients with cardiac arrest.
Design Multicenter cohort, partly prospective and partly retrospective.
Setting Seven academic or teaching hospitals from the U.S. and Europe.
Patients Individuals aged 16 or older who were comatose after return of spontaneous circulation following a cardiac arrest who had continuous EEG monitoring were included.
Interventions not applicable.
Measurements and Main Results Clinical and EEG data were harmonized and stored in a common Waveform Database (WFDB)-compatible format. Automated spike frequency, background continuity, and artifact detection on EEG were calculated with 10 second resolution and summarized hourly. Neurological outcome was determined at 3-6 months using the best Cerebral Performance Category (CPC) scale. This database includes clinical and 56,676 hours (3.9 TB) of continuous EEG data for 1,020 patients. Most patients died (N=603, 59%), 48 (5%) had severe neurological disability (CPC 3 or 4), and 369 (36%) had good functional recovery (CPC 1-2). There is significant variability in mean EEG recording duration depending on the neurological outcome (range 53-102h for CPC 1 and CPC 4, respectively). Epileptiform activity averaging 1 Hz or more in frequency for at least one hour was seen in 258 (25%) patients (19% for CPC 1-2 and 29% for CPC 3-5). Burst suppression was observed for at least one hour in 207 (56%) and 635 (97%) patients with CPC 1-2 and CPC 3-5, respectively.
Conclusions The International Cardiac Arrest Research (I-CARE) consortium database provides a comprehensive real-world clinical and EEG dataset for neurophysiology research of comatose patients after cardiac arrest. This dataset covers the spectrum of abnormal EEG patterns after cardiac arrest, including epileptiform patterns and those in the ictal-interictal continuum.
Competing Interest Statement
Potential Conflicts of Interest E.A., W.L.Z., M.M.G., M.A., P.K., V.K., J.W.L., L.J.H., S.T.H., A.S., N.G., R.S., M.A.R., G.D.C., and J.H. report no disclosures. M.V.P is the founder of Clinical Science Systems. Clinical Science Systems did not contribute funding nor played any role in the study. M.B.W. is a co-founder of Beacon Biosignals. Beacon Biosignals did not contribute funding nor played any role in the study.
Funding Statement
This study was supported by the Weil-Society of Critical Care Medicine Research Grant, American Heart Association (20CDA35310297), CURE Epilepsy Foundation (Taking Flight Award), Neurocritical Care Society (NCS research training fellowship), MIT-Philips Alliance Clinician Award, the Andrew David Heitman Neuroendovascular Research Fund, the Rappaport Foundation, the NIH (1K23NS090900, 1R01NS102190, 1R01NS102574, 1R01NS107291, R01EB030362, 1K23NS119794, T32HL007901, T90DA22759, T32EB001680), Epilepsiefonds (NEF 14-18), and Dutch Heart Foundation (2018T070).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Beth Israel Deaconess Medical Center waived ethical approval for this work. Massachusetts General Brigham waived ethical approval for this work. Yale New Haven Medical Center waived ethical approval for this work. Medisch Spectrum Twente gave ethical approval for this work. Rinjstate Hospital gave ethical approval for this work. Erasme Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Potential Conflicts of Interest
E.A., W.L.Z., M.M.G., M.A., P.K., V.K., J.W.L., L.J.H., S.T.H., A.S., N.G., R.S., M.A.R., G.D.C., and J.H. report no disclosures.
M.V.P is the founder of Clinical Science Systems. Clinical Science Systems did not contribute funding nor played any role in the study. M.B.W. is a co-founder of Beacon Biosignals. Beacon Biosignals did not contribute funding nor played any role in the study.
Study Funding:
This study was supported by the Weil-Society of Critical Care Medicine Research Grant, American Heart Association (20CDA35310297), CURE Epilepsy Foundation (Taking Flight Award), Neurocritical Care Society (NCS research training fellowship), MIT-Philips Alliance Clinician Award, the Andrew David Heitman Neuroendovascular Research Fund, the Rappaport Foundation, the NIH (1K23NS090900, 1R01NS102190, 1R01NS102574, 1R01NS107291, R01EB030362, 1K23NS119794, T32HL007901, T90DA22759, T32EB001680), Epilepsiefonds (NEF 14-18), and Dutch Heart Foundation (2018T070).
